| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20024814 | HPV | ENSG00000153253.20 | protein_coding | SCN3A | No | No | 6328 | Q9C007 Q9NY46 |
| TVIS20030919 | HPV | ENSG00000153253.20 | protein_coding | SCN3A | No | No | 6328 | Q9C007 Q9NY46 |
| TVIS20030920 | HPV | ENSG00000153253.20 | protein_coding | SCN3A | No | No | 6328 | Q9C007 Q9NY46 |
| TVIS44032001 | HTLV-1 | ENSG00000153253.20 | protein_coding | SCN3A | No | No | 6328 | Q9C007 Q9NY46 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | SCN3A |
|---|---|
| DrugBank ID | DB00252 |
| Drug Name | Phenytoin |
| Target ID | BE0002082 |
| UniProt ID | Q9NY46 |
| Regulation Type | |
| PubMed IDs | 15922564; 15805193 |
| Citations | Lucas PT, Meadows LS, Nicholls J, Ragsdale DS: An epilepsy mutation in the beta1 subunit of the voltage-gated sodium channel results in reduced channel sensitivity to phenytoin. Epilepsy Res. 2005 May;64(3):77-84.@@Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom M, Sen A, Shorvon SD, Sander JW, Wood NW, Goldstein DB: Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5507-12. Epub 2005 Apr 1. |
| Groups | Approved; Vet_approved |
| Direct Classification | Phenylhydantoins |
| SMILES | O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1 |
| Pathways | Fosphenytoin (Antiarrhythmic) Action Pathway; Fosphenytoin (Antiarrhythmic) Metabolism Pathway; Phenytoin (Antiarrhythmic) Action Pathway |
| PharmGKB | PA450947 |
| ChEMBL | CHEMBL16 |
